A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation with an Intravenous Formulation of ARGX-113 in Healthy Male Subjects.

Completed

Conditions: myasthenia gravis
primairy immunne thrombocytopeny
10003816

Registration Number: NL-OMON46383

Lead Sponsor: argenx bvba

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

1. Male, between 18-55 years of age, inclusive, on the day of signing the Informed Consent Form (ICF).
2. Body mass index (BMI) between 18-30 kg/m2, inclusive with a weight of at least 50 kg and no more than 100 kg, inclusive (only for subjects receiving Treatment A, B and D) at Screening and prior to first dosing. For subjects in Treatment subset C1 a body weight between 50 and 70 kg (inclusive) and for subjects in Treatment subset C2 a body weight between 80 and 100 kg (inclusive) at Screening and prior to first dosing.
3. Willingness and ability to understand the purpose and risks of the study and provide signed and dated informed consent prior to any procedures and be available for all study visits.
4. Non-vasectomized male subjects having a female partner of childbearing potential must agree to the use of an effective method of contraception until 90 days after the last administration of study drug.
5. Subjects have to agree not to donate sperm until 90 days after the last administration of study drug.
6. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and laboratory findings.
7. Agree to discontinue and refrain from intake of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements such as Ginkgo biloba or St John*s wort), except occasional paracetamol use (maximum dose of 2 g/day and maximum of 10 g/2 weeks), at least 2 weeks prior to the first study drug administration. In addition, subjects must agree to the prohibitions and restrictions for this study.
8. Subject is a non-smoker, and not using any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to Screening.
9. Negative urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) at Screening and Day -1.
10. Negative alcohol breath test at Screening and Day-1.
11. Oral body temperature < 38.0°C at Screening and prior to dosing on Day 1.

Exclusion Criteria

1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
2. Active infection; a recent serious infection (i.e., requiring injectable antimicrobial therapy or hospitalization) within the 8 weeks prior to screening.
History or active infection with viral infection with human immunodeficiency virus (seropositivity to HIV-1 or -2 antibodies).
Active or chronic viral infection with hepatitis B virus (HBV) serologically defined as: HBsAg positive or (Anti-HBs negative and anti-HBc positive.
Active infection with hepatitis C virus (HCV) or known seropositivity.
Subjects must have a negative TB Quantiferon test at screening.
Subjects with an undetermined Quantiferon TB result will be allowed one retest, if not negative on retesting, the subject will be excluded
3. Subjects with known clinically relevant immunological disorders.
4. History of severe allergic or anaphylactic reactions.
5. Known history or any symptom of clinically significant illness in the 6 months before the first study drug administration.
6. Presence or having sequelae of gastrointestinal, liver, kidney or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
7. History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
8. Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g., QTcF > 450 ms [millisecond], or a known long QT syndrome). A first degree heart block or sinus arrhythmia will not be considered as a significant abnormality.
9. Clinically relevant abnormalities detected on vital signs prior to first dosing.
10. Significant blood loss (including blood donation [> 500 mL]), or had a transfusion of any blood product within 12 weeks prior to the initial study drug administration or plan one within 4 weeks after the end of the study.
11. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months preceding the initial study drug administration.
12. The subject has a history of consuming more than 21 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit = 330 mL of beer, 110 mL of wine or 28 mL of spirits).
13. Consumption of a large quantity of coffee, tea (> 6 cups per day) or equivalent.
14. Concurrent participation or participation within 90 days prior to the initial study drug administration in a drug/device or biologic investigational research study.
15. Administration of a vaccine within 60 days prior to initial study drug administration.
16. Administration of any systemic immunosuppressant agent within 6 months prior to initial study drug administration.
17. Administration of any systemic steroid within 2 months prior to initial study drug administration.
18. Administration of an injectable drug within 30 days prior to the initial study drug administration.
19. Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof who is directly involved in the conduct of the study.
20. Any condition or circumstances that in the opinion of the investigator may make

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint:<br /><br>Primary pharmacokinetic parameter is AUC0-inf.<br /><br><br /><br></p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints:<br /><br>* Safety parameters include vital signs, ECG and (S)AEs, hematology, blood<br /><br>chemistry and urinalysis.<br /><br>* Pharmacodynamic parameters are Total Immunoglobulin G (IgG) and IgG subtype<br /><br>(IgG 1, IgG 2, IgG 3, and IgG 4) levels and IgA and IgM levels.<br /><br>* Secondary pharmacokinetic parameters are Cmax, Tmax, AUC0-t, AUC0-72,<br /><br>AUC0-96, AUC0-336, t1/2, CL, Vz, Vz/F and CL/F.<br /><br>* Immunogenicity parameter is the individual serum titer of ADA directed<br /><br>against ARGX- 113.</p><br>